A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in each treatment arm.
Epistemonikos ID: 56efc6955677173845b9c46336ebacb44fc49df7
First added on: May 04, 2024